2019-05-03T12:05:53-05:00 2018-06-30 EISNERAMPER LLP 750 THIRD AVENUE NEW YORK NY 100172703 990 2017-07-01 133540234 THE AARON DIAMOND AIDS RESEARCH CENTER FOR the city of new york % KEVIN O'ROURKE AARO 2127250018 455 FIRST AVENUE 7TH FL NEW YORK NY 10016 DAVID HO President 2124485150 2019-05-02 true CANDICE METH P01306891 2129498700 64.238.150.4 26505220191235000003 2019-05-03 P BF89B92ADF6B774FBF76079CE69737A6688C4B95 45E03A01E385EA2FD4321D9DC7B70482997C2D58 2017 2019-02-21 02:37:17Z DR DAVID HO 455 FIRST AVENUE NEW YORK NY 100169102 33754581 false X WWW.ADARC.ORG X 1988 NY AIDS RESEARCH 11 11 60 6 5579 55225 10462429 10656034 204271 56072 1828704 7896351 0 0 12495404 18608457 0 0 0 0 7721888 7301549 0 0 0 6952779 8065704 14674667 15367253 -2179263 3241204 67617321 69338106 4157969 5597200 63459352 63740906 AIDS RESEARCH false false 12357667 56072 THE AARON DIAMOND AIDS RESEARCH CENTER (ADARC) is the world's largest private hiv/aids research center. ADARC is committed to finding solutions to end the aids epidemic by conducting basic discovery research, and by developing novel therapies, vaccines and other prevention strategies. 12357667 true true false false false false false false false true true true false false false true true false false false true false false false false false false false false true false false false false false false false false false false false false false false false false false true 40 0 true 60 true true true false false false false false false false false false X 11 11 false false false false false false false true true false false true true true true true true true true false CA CT DC FL IL MD MA NJ NY OH PA VA X KEVIN O'ROURKE 2124485150 455 FIRST AVENUE NEW YORK NY 100169102 X GERALD FRIEDLAND MD CHAIRMAN OF THE BOARD 1.0 0.0 X X 0 0 0 SUKI TERRADA PORTS SECRETARY 1.0 0.0 X X 0 0 0 SAVIO TUNG TREASURER 1.0 0.0 X X 0 0 0 blayne cutler md phd DIRECTOR 1.0 0.0 X 0 0 0 MARTIN S HIRSCH MD DIRECTOR 1.0 0.0 X 0 0 0 MAY-KIN HO PHD DIRECTOR 1.0 0.0 X 0 0 0 TIMOTHY O'CONNOR PHD Director 1.0 0.0 X 0 0 0 DEMETRE DASKALAKIS MD DIRECTOR 1.0 0.0 X 0 0 0 DIANA VINOLY Director 1.0 0.0 X 0 0 0 DAVID S PERLIN PHD DIRECTOR 1.0 0.0 X 0 0 0 WALTER WANG director 1.0 0.0 X 0 0 0 Dafna Bar-Sagi PHD DIRECTOR 1.0 0.0 X 0 0 0 DR DAVID D HO CHIEF EXECUTIVE OFFICER 35.0 0.0 X 648457 0 94731 KEVIN O'ROURKE CHIEF FINANCIAL OFFICER 35.0 0.0 X 275409 0 57231 STEPHANIE SOZOMENU CHIEF OPERATING OFFICER 35.0 0.0 X 292877 0 57231 MORIYA TSUJI SCIENTIST 35.0 0.0 X 170943 0 43731 YAOXING HUANG SCIENTIST 35.0 0.0 X 206441 0 47581 MARTIN MARKOWITZ INVESTIGATOR SCIENTIST 35.0 0.0 X 237536 0 52742 VINCENT SAHI CORE FACILITIES MANAGER 35.0 0.0 X 133750 0 37527 XUELING WU SCIENTIST 35.0 0.0 X 133780 0 37570 2099193 0 428344 13 false true false LORD AECK SARGENT 1175 PEACHTREE ST NE SUITE 2400 ATLANTA GA 30361 ARCHITECT 666481 CS BUILDING SERVICES 152 TOLEDO STREET FARMINGDALE NY 11735 BUILDING SERVICES 327042 ADVANCED TECHNOLOGY 20 CEDAR STREET SUITE 104 NEW ROCHELLE NY 10801 COMPUTER SUPPORT 188131 CRYOSTAR INDUSTRIES 109 URBAN AVENUE WESTBURY NY 11590 REFRIGERATOR 115136 EISNERAMPER LLP 750 THIRD AVENUE NEW YORK NY 10017 AUDITOR 106000 5 4872435 5783599 10656034 REVENUE FROM CLINICAL TRIALS 541380 56072 56072 56072 5179805 5579 5174226 0 0 0 0 0 17862670 15146124 2716546 2716546 2716546 0 0 0 0 0 0 0 0 0 0 18608457 56072 5579 7890772 0 0 0 0 1318313 932722 385591 0 3461454 2449022 1012432 657854 465440 192414 1550484 1096987 453497 313444 221765 91679 0 7421 7421 94000 94000 0 0 187700 187700 759208 476152 283056 0 92478 78512 13966 0 0 1145526 986228 159298 262456 229144 33312 0 0 0 0 156280 123461 32819 308747 266550 42197 UTILITIES 311167 308895 2272 LAB SUPPLIES 837860 837860 ANIMAL FEES 152010 152010 RESEARCH SUBCONTRACTS 3576145 3576145 174706 156774 17932 15367253 12357667 3009586 0 1716277 661334 2405816 13369794 1359738 1157584 0 0 0 0 0 0 0 0 0 0 601528 446287 24977413 22978952 318557 1998461 36260068 30211527 24955337 21493119 0 0 0 0 0 0 67617321 69338106 1482593 1418096 0 0 2675376 4179104 0 0 0 0 0 0 0 0 0 0 0 0 4157969 5597200 X 52246716 52202734 6212636 6538172 5000000 5000000 63459352 63740906 67617321 69338106 3241204 -2959650 X false true X true true true X 16328011 13542106 11962028 10462429 10656034 62950608 0 0 0 0 0 0 0 0 0 0 0 0 16328011 13542106 11962028 10462429 10656034 62950608 14502045 48448563 2973214 2114186 1641406 1436270 5179805 13344881 0 0 0 0 5579 5579 0 0 0 0 0 0 76301068 837599 0.63497 0.70421 X 22246408 392663 14471713 8167358 20909389 2074290 737271 22246408 22339149 -681607 748153 20909389 22880697 180815 722363 22339149 21092243 2482952 694498 22880697 0.61220 0.38780 false false 19087169 19087169 1367818 1945766 1821259 124507 3944478 2070524 506136 1998461 FUNDS OF FUNDS 20862223 F LIMITED PARTNERSHIPS 630896 F 21493119 0 0 X 15648807 -2959650 -2959650 18608457 18608457 15367253 15367253 15367253 FORM 990, SCHEDULE D, PART V, QUESTION 4 USE OF FUND ENDOWMENTS: THE CENTER'S ENDOWMENT CONSISTS OF BOTH A DONOR-RESTRICTED ENDOWMENT FUND TO BE USED FOR AIDS RESEARCH AND A FUND DESIGNATED BY THE BOARD OF DIRECTORS TO FUNCTION AS ENDOWMENT. FORM 990, SCHEDULE D, PART X, QUESTION 2 The Center is subject to the provisions of the Financial Accounting Standards Board's (the "FASB") Accounting Standards Codification ("ASC") Topic 740, "Income Taxes", relating to accounting and reporting for uncertainty in income taxes. Because of the Center's general tax-exempt status, management believes ASC Topic 740 has not had, and is not anticipated to have, a material impact on the Center's financial statements. Central America and the Caribbean Investments 7861496 7861496 7861496 true false false false true false Part I, Line 3, Column (f) Amount included in Schedule F is reported on the accrual basis of accounting. Part IV Foreign Investments The Center maintains investments in several foreign funds. The Center filed the appropriate 926 form related to a transfer. However, the threshold for filing a FORM 8865 was not met and, accordingly, the Center did not file form 8865. X X X X X false true false false false false false false false DR DAVID D HO CHIEF EXECUTIVE OFFICER 648457 0 0 0 0 0 78000 0 16731 0 743188 0 0 0 KEVIN O'ROURKE CHIEF FINANCIAL OFFICER 275409 0 0 0 0 0 40500 0 16731 0 332640 0 0 0 STEPHANIE SOZOMENU CHIEF OPERATING OFFICER 292877 0 0 0 0 0 40500 0 16731 0 350108 0 0 0 MORIYA TSUJI SCIENTIST 170943 0 0 0 0 0 27000 0 16731 0 214674 0 0 0 YAOXING HUANG SCIENTIST 206441 0 0 0 0 0 30850 0 16731 0 254022 0 0 0 MARTIN MARKOWITZ INVESTIGATOR SCIENTIST 237536 0 0 0 0 0 36011 0 16731 0 290278 0 0 0 VINCENT SAHI CORE FACILITIES MANAGER 133750 0 0 0 0 0 20796 0 16731 0 171277 0 0 0 AGEGNEHU GETTIE SCIENTIFIC PROGRAM ADMIN. 118588 0 0 0 0 0 18016 0 16731 0 153335 0 0 0 XUELING WU SCIENTIST 133780 0 0 0 0 0 20839 0 16731 0 171350 0 0 0 SCHEDULE J, PART I, QUESTION 3 COMPENSATION PRACTICES: The executive compensation subcommittee's purpose is to review the ceo's employment agreement to ensure that the CEO's compensation package represents reasonable renumeration for the services performed and compliance with all applicable Federal, State, and Local laws. The subcommittee engaged an independent compensation consultant and completed a compensation study and report. The information provided by the compensation consultant is used by the compensation subcommittee to ensure that the terms of compensation recommended by this committee, including any non-monetary compensation, are considered reasonable. The recommendations are then brought to the full Board for approval. The compensation of other officers and key personnel are reviewed by the CEO for reasonableness. Promotions to these levels are recommended by the CEO and brought to the full Board for approval. part i, line 4b, During 2017, the Center contributed $1,000 and $17,500 into a 457(b) and 457(f) plan, respectively, for the CEO. FORM 990, PART VI, QUESTION 11 Governing body review of form 990: The Center's governing board receives a copy of the Form 990 prior to electronic Filing with the internal revenue service. The Center's Audit Committee is responsible for reviewing and approving the 990 for submission. FORM 990, PART VI, QUESTION 12C Monitoring and enforcement of compliance with conflicts of interest: Officers and directors are required, on an annual basis, to review, disclose potential conflicts, and sign the center's conflict of interests policy. FORM 990, PART VI, QUESTION 15 COMPENSATION PRACTICES: The executive compensation subcommittee's purpose is to review the ceo's employment agreement to ensure that the CEO's compensation package represents reasonable renumeration for the services performed and compliance with all applicable Federal, State, and Local laws. The subcommittee engaged an independent compensation consultant and completed a compensation study and report. The information provided by the compensation consultant is used by the compensation subcommittee to ensure that the terms of compensation recommended by this committee, including any non-monetary compensation, are considered reasonable. The recommendations are then brought to the full Board for approval. The compensation of other officers and key personnel are reviewed by the CEO for reasonableness. Promotions to these levels are recommended by the CEO and brought to the full Board for approval. FORM 990, PART VI, QUESTION 17 STATES: AL,AK,AZ,AR,CA,CO,CT,DE,DC,FL,GA,HI,ID,IN,IA,KS,KY,LA,ME,MD,MA,MI,MN,MS,MO ,MT,NE,NV,NH,NJ,NC,ND,OH,OK,OR,PA,RI,SC,SD,TN,TX,UT,VT,VA,WA,WV,WI,WY FORM 990, PART VI, QUESTION 19 GOVERNING DOCUMENTS AND ORGANIZATIONAL POLICIES: THE CENTER MAKES AVAILABLE THE MISSION STATEMENT AND THE ANNUAL FINANCIAL REPORT ON ITS WEBSITE. THE BY-LAWS, IRS FORM 990, AND CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST. EXTENSION An EXTENSION OF TIME TO FILE THE FORM 990 was electronically FILED.